Pharma White Papers

Home » Pharma White Papers
8 08, 2019

Data Integrity – A Closer Look

Data integrity remains a perennial hot topic impacting the pharma biotech industry and the trend has been picking up steam; the number of data integrity-related warning letters has increased consistently since 2010. A number of new guidance documents came out in 2016 by FDA, MHRA, EMA PIC/S and the WHO and yet companies continue [...]

7 02, 2019

The vital importance of winning the talent war & investing in education

I recently had a meeting with a CEO to help solve his company’s pain points. He was in need of a big dose of a strong analgesic. Falling prices, suffocating complexity, poor product development, supply chain disruption, product shortages, increasing operational costs and unhappy investors were taking him beyond his pain threshold. One pain [...]

15 01, 2019

The future of the pharmaceutical industry

YOUR CHANCE TO CONTRIBUTE Ever participated in one of those benchmarking exercises? You know what I mean. When a (usually) fresh-faced consultant asks lots of questions and fills in a spreadsheet comparing what you do with your competitors. Well, beware. BENCHMARKING CAN BE DANGEROUS Trying to copy and follow others [...]

6 12, 2017

How the Mighty Fall: Why Being RISK SMART Will Decide Your Future

After chairing a session on risk at the recent Pharma Integrates 2017, Martin Lush, Global Vice President, NSF Pharma Biotech and Medical Devices, was compelled to put "pen to paper" to get people thinking and debating this issue before it’s too late!  How the pharmaceutical industry manages risk is appalling. There you go. I’ve said it. I’ve [...]

21 11, 2017

Data-Driven Personas Help Take the Edge Off Risked-Based Life Science Contracts

Few recent trends have had as profound an effect on life sciences organisations as the healthcare industry’s transition to value-based care with its focus on outcomes. No longer is it enough to deliver drugs and devices that have proven to be effective in clinical trials. Today, life sciences organisations are being asked to assume part [...]

1 09, 2017

In Vivo Models to Target Respiratory Diseases

Intuitive analysis and insights into methods of optimising in vivo efficacy studies and what developments might be coming to fruition in the future Scientists involved in biopharmaceutical and biomedical research seek to generate the highest quality data for their studies by employing an optimal combination of in vivo and ex vivo models. The 3Rs principle [...]